News
ACUT
1.090
NaN%
--
Weekly Report: what happened at ACUT last week (0609-0613)?
Weekly Report · 4d ago
AccuStem Sciences Chairman Gabriele Cerrone buys additional 8,991 shares
Seeking Alpha · 06/13 11:41
Weekly Report: what happened at ACUT last week (0602-0606)?
Weekly Report · 06/09 10:18
Weekly Report: what happened at ACUT last week (0526-0530)?
Weekly Report · 06/02 10:23
Weekly Report: what happened at ACUT last week (0519-0523)?
Weekly Report · 05/26 10:22
Based on the provided financial report articles, I generated the title for the article: "ACUT's Financial Report: Q1 2025 Earnings and Operations Update" Please note that the title may not be exact, as the provided text does not contain a clear title. However, based on the content, I inferred the title to be related to ACUT's financial report for the first quarter of 2025.
Press release · 05/21 07:39
Weekly Report: what happened at ACUT last week (0512-0516)?
Weekly Report · 05/19 10:17
Weekly Report: what happened at ACUT last week (0505-0509)?
Weekly Report · 05/12 10:18
Weekly Report: what happened at ACUT last week (0428-0502)?
Weekly Report · 05/05 10:18
ACCUSTEM SCIENCES, INC. AND EMERITUSDX ANNOUNCE PARTNERSHIP TO COMMERCIALIZE MSC TEST FOR LUNG CANCER SCREENING
Reuters · 04/28 11:00
Weekly Report: what happened at ACUT last week (0421-0425)?
Weekly Report · 04/28 10:24
AccuStem Sciences reports share purchase by Chairman
Seeking Alpha · 04/21 11:53
ACCUSTEM SCIENCES, INC. ANNOUNCES CHAIRMAN PURCHASE OF SHARES
Reuters · 04/21 11:00
Weekly Report: what happened at ACUT last week (0414-0418)?
Weekly Report · 04/21 10:24
ACCUSTEM SCIENCES, INC. SIGNS AGREEMENT TO ACCESS BLOOD SAMPLES FROM LUNG CANCER SCREENING TRIAL TO EXPEDITE MSC COMMERCIALIZATION PLAN
Reuters · 04/16 11:00
Weekly Report: what happened at ACUT last week (0407-0411)?
Weekly Report · 04/14 10:18
Weekly Report: what happened at ACUT last week (0331-0404)?
Weekly Report · 04/07 10:17
Based on the provided financial report articles, I generated the title for the article: "Annual Report (Form 10-K) for the fiscal year ended December 31, 2024, of ACUT, Inc." Please note that the title may not be exact, as the provided text appears to be a financial report with various sections and data, and the title may not be explicitly stated.
Press release · 04/05 06:15
Weekly Report: what happened at ACUT last week (0324-0328)?
Weekly Report · 03/31 10:24
Weekly Report: what happened at ACUT last week (0317-0321)?
Weekly Report · 03/24 10:17
More
Webull provides a variety of real-time ACUT stock news. You can receive the latest news about ACCUSTEM SCIENCES INC through multiple platforms. This information may help you make smarter investment decisions.
About ACUT
AccuStem Sciences, Inc. is a clinical-stage diagnostics company. It is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. It focuses on its proprietary genomic tests, MicroRNA Signature Classifier (MSC) for patients with lung nodules and StemPrintER for patients with early-stage breast cancer. The MSC test, a 24-micro-RNA (miRNA) assay designed to help determine whether lung nodules identified by low-dose computer tomography (LDCT) screening, are benign or malignant. StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. The assay is developed to measure the stemness of tumors, or how much a tumor behaves like stem cells, which could indicate how likely a cancer is to recur or be resistant to standard treatments, ultimately impacting how patients are managed by their multidisciplinary care team.